AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02745106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency pulmonary artery denervation
Description: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
Study NCT02745106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation catheter
Description: 4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
Study NCT02745106 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Swan-Ganz catheter for right heart catheterization
Description: Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)
Study NCT02745106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swan-Ganz catheter for right heart catheterization
Description: Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)
Study NCT06523179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quantify the impact of genetic risk factors
Description: the impact of genetic risk factors for the development of NAFLD-HCC and their interaction with acquired risk factors, on the incidence of the disease in a prospective cohort of patients at risk, through a score capable of predicting NAFLD-HCC and selecting patients for whom screening is cost-effective.
Study NCT01549158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torasemide-PR
Description: Single oral dose of torasemide PR 10 mg
Study NCT01549158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide-IR
Description: Single oral dose of furosemide IR 40 mg
Study NCT03635528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100
Study NCT01549158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: torasemide-IR
Description: Single oral dose of torasemide IR 10 mg
Study NCT03546465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection
Study NCT01923519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchofiberscopy
Study NCT01704365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine with Adjuvant
Description: 0.5mL IM Injection
Study NCT01704365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine without Adjuvant
Description: 0.5ml IM Injection
Study NCT01704365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine with Adjuvant
Description: 0.5mL IM Injection
Study NCT01704365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine without Adjuvant
Description: 0.5mL IM Injection
Study NCT01704365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]
Description: 0.5mL IM Injection
Study NCT01704365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5mL IM Injection
Study NCT01704365 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL IM Injection
Study NCT04581915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazavirin (Riamilovir)
Description: Capsule - 250mg 8 hourly po
Study NCT04581915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT00566488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymus/Parathyroid Transplantation
Description: Thymus tissue, thymus donor, mother of thymus donor, \& parental parathyroid donor screened for transplant safety. Depending on T cell phenotype \& function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre \& post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis \& graft rejection.
Study NCT03879031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cluster of Clinical tests to measure lumbar stability
Description: All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~* Aberrant Movements (AM) Test,~* Active Straight Leg Raise Test (ASLR) Test,~* Supine Bridge Test (SuBT),~* Right Side Bridge Test (RBT),~* Left Side Bridge Test (LBT),~* Prone Bridge Test (PrBT),~* Passive Lumbar Extension (PLE) Test,~* Prone Instability Test (PIT).
Study NCT05233813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Body and Mind
Description: The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
Study NCT01664091 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: post-mastectomy radiation therapy (PMRT)
Study NCT01664091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tissue expander (TE)
Study NCT01664091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acellular dermal matrix (ADM)
Study NCT00748202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-Esterase Inhibitor
Description: 1000 I.E.
Study NCT04556747 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VR - Distraction
Description: Participants will be instructed to use any application.
Study NCT04556747 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VR - Biofeedback
Description: Participants will be instructed to use the Mindful Aurora application.
Study NCT01105052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help CBT-I
Description: Comparison between Bibliotherapy with and without support to a wait-list control group
Study NCT01105052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help CBT-I
Description: Comparison between Bibliotherapy with and without support to a wait-list control group
Study NCT02559167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
Study NCT02559167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol
Description: The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
Study NCT00908934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase III 50 mg (T)
Description: Given as 50 mg tablet (T)
Study NCT03635528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens
Study NCT00908934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase IIb 50 mg (R)
Description: Given as 50 mg tablet (R)
Study NCT00908934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase III 200 mg (T)
Description: Given as 400 mg (2 x 200 mg tablet (T))
Study NCT00908934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase IIb 200mg (R)
Description: Given as 400 mg (2 x 200 mg tablet (R))
Study NCT02111200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate
Description: Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
Study NCT02111200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Phenylbutyrate
Description: Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
Study NCT00111761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
Study NCT03635528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 1
Description: EMO-117
Study NCT00111761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
Study NCT00111761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
Study NCT00111761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
Study NCT03635528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens 2
Description: Proclear 1 day
Study NCT00513929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc sulphate
Description: Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
Study NCT00373503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
Study NCT03828643 — intervention group
Intervention type: DRUG
Intervention: Secukinumab
Description: Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.
Study NCT03828643 — intervention group
Intervention type: DRUG
Intervention: Secukinumab
Description: Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.
Study NCT02233543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: Delivered once daily via single-dose dry powder inhaler
Study NCT02233543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149 Placebo
Description: Placebo delivered once daily via single-dose dry powder inhaler
Study NCT03206892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laparoscopic ovarian drilling
Description: laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
Study NCT03206892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian drilling
Description: laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
Study NCT00373503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronabinol
Description: cannabinoid agonist hypothesized to decrease MJ withdrawal
Study NCT00373503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: marijuana intoxication, withdrawal and relapse assessed
Study NCT00091078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00091078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00682747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
Study NCT04165876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Motor Cortex Stimulation
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
Study NCT00091078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04165876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsolateral Prefrontal Cortex Stimulation
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
Study NCT04165876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Stimulation (DLPFC+M1)
Description: Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
Study NCT04165876 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
Study NCT04330924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Create Real-life Experience And Teamwork In Virtual Environment (CREATIVE)
Description: 3D virtual hospital environment where participants can perform physical and social interaction and presence using avatars.
Study NCT02480959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment for recurrent patellar instability
Description: Either medial plication or MPFL reconstructuion surgery
Study NCT00266227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT00266227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study NCT00266227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose
Study NCT00266227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose
Study NCT00266227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Intravenous repeating dose
Study NCT00266227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folate
Description: Intravenous repeating dose
Study NCT01378780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention for diet and physical activity
Description: The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
Study NCT01378780 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational message on skin cancer awareness
Description: Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
Study NCT01869387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Study NCT02272296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: jet injector
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
Study NCT02272296 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: jet injector
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
Study NCT02272296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pen (NovoPen IV)
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
Study NCT02272296 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional pen (NovoPen IV)
Description: 1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
Study NCT04576403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: activated mittens
Description: activated mittens (with electronic heat)
Study NCT04576403 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deactivated mittens
Description: deactivated mittens (without electronic heat)
Study NCT03828747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semorinemab
Description: Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
Study NCT03828747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
Study NCT03828747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study NCT03828747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study NCT00549393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine gluconate cloth
Description: Daily bathing
Study NCT04007380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
Study NCT04321668 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Synvisc-One
Description: SYNVISC-ONE® (Hylan G-F 20), 10 mL single-injection viscosupplement Status : CE marked (CE 0086) class III Medical Device The IP is used according to its usual dosage, administration and indication